A brief discussing findings from this year's San Antonio Breast Cancer Symposium showing that research suggests that the drug Zometa may provide patients with reduced bone loss and a lesser chance of ...

A new drug called denosumab may soon give Zometa (zoledronic acid) competition as the standard of care in treating bone metastases in patients with advanced breast cancer. Patients taking denosumab ...

A new research paper, titled "In vitro and in vivo effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers," was published on the cover of Aging Zoledronic acid ...

The efficacy of zoledronic acid after hip fracture was evaluated in 2,127 patients (1,619 women and 508 men) aged 50 years and older (N Engl J Med. 2007;357:1799-1809). The Health Outcomes and Reduced ...

Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...

BRAMPTON, Ontario--(BUSINESS WIRE)--Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL ...

Avenacy's zoledronic acid injection is available as a 4 mg/5 ml (0.8 mg per ml) single-dose vial. [Read more: Avenacy intros generic Reglan] Avenacy said that the medication will feature the company’s ...

Impact of palliative care on end-of-life management of cancer patients dying in the hospital. Assessment of the current implementation and barriers to uptake of the guidelines for the psychosocial ...

Gonadotropin-releasing-hormone (GnRH) agonists are routinely used to manage recurrent nonmetastatic prostate cancer, but the therapy results in hypogonadism, which has adverse consequences including ...

SAN ANTONIO (AP) - One of the most promising new approaches for fighting breast cancer took a stunning setback Thursday when a major study showed that a bone-building drug did not stop cancer from ...

Please provide your email address to receive an email when new articles are posted on . Graeme Jones, PhD, and colleagues randomly assigned 223 patients with symptomatic knee OA and subchondral bone ...